Clinical trials
Phase 1 Fragile X Syndrome trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
14 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2009 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 1 |
| 2021 | 1 |
| 2023 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 11 |
| Enrolling by invitation | 1 |
| Terminated | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Children's Hospital Medical Center, Cincinnati | 3 |
| Stanford University | 2 |
| Connecta Therapeutics, S.L. | 1 |
| Guido A. Davidzon, MD, SM | 1 |
| Healx AI | 1 |
| Institute for Neurodegenerative Disorders | 1 |
| Novartis Pharmaceuticals | 1 |
| Queen's University, Belfast | 1 |
| Seaside Therapeutics, Inc. | 1 |
| University Hospital, Tours | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fragile X Syndrome | 14 |
| Intellectual Disability | 4 |
| Autistic Disorder | 2 |
| Down Syndrome | 2 |
| Alzheimer Disease | 1 |
| Angelman Syndrome | 1 |
| Attention Deficit Disorder with Hyperactivity | 1 |
| Autism Spectrum Disorder | 1 |
| Central Nervous System Diseases | 1 |
| Cognitive Dysfunction | 1 |
Trials
Showing 51 to 14 of 14. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.